Harvard Accelerator Program, Proving Its Mettle with Startups and Pharma Partnerships, Looks to Raise Big New Fund
The five-year goal for the Accelerator Fund is for one or two drug candidates born from Harvard research to be in Phase 1 clinical trials, and for at least one of the program’s startups to enter into exit talks with another company.
“The Accelerator Fund, which Xconomy wrote about in early 2008, was created to help Harvard scientists commercialize their inventions by forming industry partnerships, licensing technology, and starting new companies, primarily in life sciences and biomedical fields. As technology development head and senior associate provost Isaac Kohlberg puts it, “The pipelines of Harvard were empty.” The school “suffered from a branding issue with stakeholders about the role of technology development,” he says.
Kohlberg and his team, which includes Curtis Keith, chief scientific officer of the Accelerator Fund, were brought in to overhaul Harvard’s tech transfer and development offices…”